Didkowska, J.A.; Wojciechowska, U., Barańska, K.; Miklewska, M.; Michałek, I.; Olasek, P. Nowotwory złośliwe w Polsce w 2021 roku. Raport roczny. Narodowy Instytut Onkologii. Krajowy Rejestr Nowotworów. Warszawa 2023. ISSN 0867-8251
Basta, A. et al., Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. Curr. Gyn. Oncol. 2017, 15, 5-23.
DOI: https://doi.org/10.15557/CGO.2017.0001
Jassem, J.; Kordek, R. Onkologia. Podręcznik dla studentów i lekarzy. Ed. 5. 2019. Via Medica. 243-249
Zheng, F. et al. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed. Pharmacother. 2020, 123, Art. No: 109661. doi: 10.1016/j.biopha.2019.10966
DOI: https://doi.org/10.1016/j.biopha.2019.109661
Herceg, Z.; Wang, Z.-Q. Functions of poly(ADP-ribose)polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res. 2001, 477(1-2), 97-110. doi: 10.1016/s0027-5107(01)00111-7.
DOI: https://doi.org/10.1016/S0027-5107(01)00111-7
Lindahl, T. Instability and decay of the primary structure of DNA. Nature 1993, 362(6422), 709-715. doi: 10.1038/362709a0
DOI: https://doi.org/10.1038/362709a0
Hoeijmakers, J.H., Genome maintenance mechanisms for preventing cancer. Nature 2001, 411(6835), 366-74. doi: 10.1038/35077232
DOI: https://doi.org/10.1038/35077232
Foo, T.; George, A.; Banerjee, S. PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. Genes Chromosomes Cancer 2021, 60(5), 385-397. doi: 10.1002/gcc.22935
DOI: https://doi.org/10.1002/gcc.22935
Smith, M.; Pothuri, B. Appropriate Selection of PARP Inhibitors in Ovarian Cancer. Curr. Treat. Options Oncol. 2022, 23(6), 887-903. doi: 10.1007/s11864-022-00938-4
DOI: https://doi.org/10.1007/s11864-022-00938-4
Lynparza Product Information. European Medicines Agency.
Paulino, E. Lessons learned with a longer follow-up from SOLO 1. J. Gynecol. Oncol. 2023, 34(1), Art. No: e29. doi: 10.3802/jgo.2023.34.e29
DOI: https://doi.org/10.3802/jgo.2023.34.e29
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18(9), 1274-1284. doi: 10.1016/S1470-2045(17)30469-2
DOI: https://doi.org/10.1016/S1470-2045(17)30469-2
Ray-Coquard, I. et al., Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N. Engl. J. Med. 2019, 381(25), 2416-2428. doi: 10.1056/NEJMoa1911361
DOI: https://doi.org/10.1056/NEJMoa1911361
Rubraca Product Information. European Medicines Agency.
Coleman, R.L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 2017, 390(10106), 1949-1961. doi: 10.1016/S0140-6736(17)32440-6
DOI: https://doi.org/10.1016/S0140-6736(17)32440-6
Monk, B.J. et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J. Clin. Oncol. 2022, 40(34), 3952-3964. doi: 10.1200/JCO.22.01003
DOI: https://doi.org/10.1200/JCO.22.01003
Zejula Product Information. European Medicines Agency.
González-Martín, A. et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2019, 381(25), 2391-2402. doi: 10.1056/NEJMoa1910962
DOI: https://doi.org/10.1056/NEJMoa1910962
Mirza, M.R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 2016, 375(22), 2154-2164. doi: 10.1056/NEJMoa1611310.
DOI: https://doi.org/10.1056/NEJMoa1611310
English
Język Polski
